At Novawham, the management of each clinical endpoint study is tailored to each sponsor’s requirements.
Novawam understands that new products in medical and commercial success depend on the ability of CROs (Contract Research Organizations) to collect and analyze research data and prepare comprehensive reports in a safe and effective manner.
The Novam Management Clinical Endpoint Study requires a large population of patients with common ailments that can be treated in the outpatient clinic. These studies often involve thousands of patients and we have received 20 ANDA and NDA approvals since 2001. We have more than 2,000 research sites across the United States, ensuring that all selected sites meet the requirements of each study and the high standards of Novawam.